Expression of Tgfβ1 and Inflammatory Markers in the 6-hydroxydopamine Mouse Model of Parkinson's Disease

被引:41
|
作者
Haas, Stefan Jean-Pierre [1 ]
Zhou, Xiaolai [2 ,3 ]
Machado, Venissa [2 ,4 ,5 ]
Wree, Andreas [1 ]
Krieglstein, Kerstin [4 ]
Spittau, Bjoern [4 ]
机构
[1] Univ Rostock, Med Ctr, Inst Anat, D-18055 Rostock, Germany
[2] Univ Freiburg, Inst Anat & Cell Biol, Dept Mol Embryol, Hugstetter Str 55, D-79106 Freiburg, Germany
[3] Cornell Univ, Weill Inst Cell & Mol Biol, Dept Mol Biol & Genet, Ithaca, NY USA
[4] Univ Freiburg, Spemann Grad Sch Biol & Med SGBM, Hugstetter Str 55, D-79106 Freiburg, Germany
[5] Univ Freiburg, Fac Biol, Hugstetter Str 55, D-79106 Freiburg, Germany
来源
关键词
6-OHDA; microglia; astrocytes; Tnfu; Tgf beta 1; GROWTH-FACTOR BETA-1; MICROGLIAL ACTIVATION; TIME-COURSE; 6-OHDA; SYSTEM; CELLS; NEURONS; NG2; MACROPHAGES; ASTROCYTES;
D O I
10.3389/fnmol.2016.00007
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Parkinson's disease (PD) is a neurodegenerative disorder that is characterized by loss of midbrain dopaminergic (mDA) neurons in the substantia nigra (SN). Microgliamediated neuroinflammation has been described as a common hallmark of PD and is believed to further trigger the progression of neurodegenerative events. Injections of 6-hydroxydopamine (6-OHDA) are widely used to induce degeneration of mDA neurons in rodents as an attempt to mimic PD and to study neurodegeneration, neuroinflammation as well as potential therapeutic approaches. In the present study, we addressed microglia and astroglia reactivity in the SN and the caudatoputamen (CPu) after 6-0HDA injections into the medial forebrain bundle (MFB), and further analyzed the temporal and spatial expression patterns of pro-inflammatory and anti-inflammatory markers in this mouse model of PD. We provide evidence that activated microglia as well as neurons in the lesioned SN and CPu express Transforming growth factor beta 1 (Tgf beta 1), which overlaps with the downregulation of pro-inflammatory markers Tnfu, and iNos, and upregulation of anti-inflammatory markers Yrn /and Argl. Taken together, the data presented in this study suggest an important role for Tgf beta 1 as a lesion-associated factor that might be involved in regulating microglia activation states in the 6-OHDA mouse model of PD in order to prevent degeneration of uninjured neurons by microglia-mediated release of neurotoxic factors such as Info and nitric oxide (NO).
引用
收藏
页数:14
相关论文
共 50 条
  • [1] The 6-hydroxydopamine model of Parkinson's disease
    Simola, Nicola
    Morelli, Micaela
    Carta, Anna R.
    NEUROTOXICITY RESEARCH, 2007, 11 (3-4) : 151 - 167
  • [2] The 6-Hydroxydopamine model of parkinson’s disease
    Nicola Simola
    Micaela Morelli
    Anna R. Carta
    Neurotoxicity Research, 2007, 11 : 151 - 167
  • [3] Sensorimotor assessment of the unilateral 6-hydroxydopamine mouse model of Parkinson's disease
    Glajch, Kelly E.
    Fleming, Sheila M.
    Surmeier, D. James
    Osten, Pavel
    BEHAVIOURAL BRAIN RESEARCH, 2012, 230 (02) : 309 - 316
  • [4] The 6-hydroxydopamine Rat Model of Parkinson's Disease
    Guimaraes, Rayanne Poletti
    Ribeiro, Danilo Leandro
    dos Santos, Keila Bariotto
    Godoy, Livea Dornela
    Correa, Mirella Rosine
    Padovan-Neto, Fernando Eduardo
    JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2021, (176):
  • [5] Effects of puerarin on gait disturbance in a 6-hydroxydopamine mouse model of Parkinson's disease
    Kim, Na-Hyun
    Goto, Yukiori
    Lee, Young-A
    PHARMACOLOGICAL REPORTS, 2025, 77 (01) : 247 - 259
  • [6] Lymphocytes reduce nigrostriatal deficits in the 6-hydroxydopamine mouse model of Parkinson's disease
    Ip, Chi Wang
    Beck, Sandra K.
    Volkmann, Jens
    JOURNAL OF NEURAL TRANSMISSION, 2015, 122 (12) : 1633 - 1643
  • [7] Activin A Protects Midbrain Neurons in the 6-Hydroxydopamine Mouse Model of Parkinson's Disease
    Stayte, Sandy
    Rentsch, Peggy
    Li, Kong M.
    Vissel, Bryce
    PLOS ONE, 2015, 10 (04):
  • [8] Lymphocytes reduce nigrostriatal deficits in the 6-hydroxydopamine mouse model of Parkinson’s disease
    Chi Wang Ip
    Sandra K. Beck
    Jens Volkmann
    Journal of Neural Transmission, 2015, 122 : 1633 - 1643
  • [9] Neuroprotection by safinamide in the 6-hydroxydopamine model of Parkinson's disease
    Sadeghian, M.
    Mullali, G.
    Pocock, J. M.
    Piers, T.
    Roach, A.
    Smith, K. J.
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2016, 42 (05) : 423 - 435
  • [10] Molecular Profiling of a 6-Hydroxydopamine Model of Parkinson’s Disease
    Sang J. Na
    Anthony G. DiLella
    Edward V. Lis
    Keith Jones
    David M. Levine
    David J. Stone
    J. F. Hess
    Neurochemical Research, 2010, 35 : 761 - 772